Tumor Models


Published on

  • Be the first to comment

  • Be the first to like this

Tumor Models

  1. 1. Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comA) Modeling and Simulation for Effective Translation of PK/PD, Efficacy and Toxicity Jay Mettetal, Senior Scientist, Millennium PharmaceuticalsB) Optimizing your Current Tumor Imaging Capabilities to more Accurately Visualize the Impact of a Drug on a Tumor Dai Fukumura, Associate Professor of Radiation Oncology, Massachusetts General HospitalC) Exploring Patient-Derived Tumor Xenografts to Enhance Data Sets and Improve Efficacy Predictions John Tentler, Associate Professor, University of ColoradoNapoleone FerraraDistinguished ProfessorUC San DiegoGeorge NaumovSenior Research BiologistMerckRichard GregoryLaboratory HeadSanofiBirgit SchultesSenior Research DirectorMomenta PharmaceuticalsTerri Van DykeHead of Cancer Pathways &MechanismsNIHAnderson ClarkDirector of in vivo PharmacologyEMD SeronoChing Ching LeowSenior ScientistMedImmuneFrank GibbonsSenior ScientistAstraZenecaDhaval ShahSenior ScientistPfizerLi YuResearch DirectorRoche• Understand how the leading drug developers are using preclinicaltumor models that are superior in predicting clinical efficacy• Learn how to generate tumor models that will lead to betterdecision making moving into the clinic• Discover how to use novel tumor models to get a broader, moreaccurate view of your drug activity• Overcome the limitations of current models and bring moleculesinto the clinic with more confidence• Meet with world renowned experts in industry and academia toexpand your personal network of tumor model professionals23 Expert Speakers Including:Keynote Presentation From:Benefits of AttendingBookearlyandsaveupto$500Speaking CompaniesWorkshops: 23rd July 2013
  2. 2. Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comTumor Models Boston 23rd – 25th July 2013Keynote Speaker:“I got much more out of thisconference than from the recentAACR conference”AstraZeneca“Very valuable and usefulinformation. One of the bestmeetings I’ve ever attended.”Millennium“It exceeded my expectations.The talks were high quality andthe interaction among participantswas excellent.”Genentech“Very good scientific content andstimulating discussions”Metabolon“Excellent presentations coveringa good spread of approaches andtechnologies”MedImmune“The focused meetings are veryuseful. It brings the right peopletogether”ZymeworksTumor Models will arm you with the capability needed to build and interpret thevery best preclinical oncology models.This groundbreaking, pharma-focussed meeting is rich with data on the leadingedge preclinical models that are better predictors of clinical efficacy. Decidewhich molecules to move forward into the clinic with the highest possibleconfidence, using data that’s more reflective of clinical performance. Worldrenowned experts will be sharing their secrets for designing and using tumormodels. You’ll leave with the latest techniques to humanize your models andmake better translational decisions. Decisions that will slash the current attritionrate in your oncology pipeline and ultimately lead to effective therapeutics forpatients.Tumor Models gives you timely access to the industry intelligence, combinedwith academic insight, that you can’t find anywhere else. Cutting edge data,exclusive research, opportunities to collaborate – this meeting is a must for thosecommitted to bringing successful cancer drugs into the clinic.How will Tumor Models help you develop and apply better preclinical models?• Listen to groundbreaking keynote presentations on current tumor models fromresearch leaders in the field, including Napoleone Ferrara and Terri Van Dyke• Overcome challenges of preclinical model development using examples ofpatient-derived tumor models from EMD Serono, MedImmune, Verastem andMillennium Pharmaceuticals• Determine how Novartis overcome the limitations of genetically engineeredmouse models to better investigate tumor development• Learn how Pfizer are using heterotopic tumor models to allow a more realisticassessment of drug efficacy in patients• Understand the approach Genentech takes in developing clinically relevantmodels for metastatic cancers• Explore how Roche select an appropriate molecular entity as early as possibleto minimize later stage attrition• Engage in interactive panel discussions addressing the issues of preclinical datainterpretation with Eisai, ImmunoGen and Jounce Therapeutics, amongst others.Attendees will leave with a list of practical ideas to optimize their currenttumor models. Meet and network with cancer researchers, academics and drugdevelopers to ensure maximum quality of discussions and add valuable contactsto your network.This meeting is for:• Drug developers who are looking to optimize current tumor models andexplore practical alternatives to ensure the effective translation of preclinicaldata into a clinical setting• Small biotechs & model providers looking to showcase their optimized andalternative tumor model platforms• Academics and researchers looking to learn more about the most up todate tumor models, together with alternate animal systems. It’s also a greatopportunity to look for collaborations and funding• CRO’s specializing in preclinical drug development and oncologySearch groups for: Tumour Modelsto join the online community.Napoleone FerraraDistinguished ProfessorUC San DiegoNapoleone is credited with identifying the humanVEGF gene and describing its proangiogenicproperties, which formed the basis for thedevelopment of Genentech’s bevacizumab.In 2013 he was awarded the $3 millionBreakthrough Prize in Life Sciences for his work.Access the Right Models and Design the Future ofYour Oncology Pipeline with ConfidenceWho Should Attend?Hear what Previous HansonWade Attendees have to say
  3. 3. Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comTumor Models Boston 23rd – 25th July 20138.00 Registration, Coffee & Networking8.55 Chair’s Opening Remarks Terri Van Dyke, Head of Cancer Pathways & Mechanisms,NIH9.00 Preclinical Tumor Models – How Predictive Are They?• A detailed overview of the challengesthe pharmaceutical industry face withtumor models• Overcoming issues related to translatingdata from animal models into the clinic• Strategies to drive forward the field of tumormodels and improve clinical outcome Napoleone Ferrara, Distinguished Professor, UC San DiegoPlus extended Q&A session – What issues do we, the industry,need to address at Tumor Models10.00 Speed Networking A revolutionary and highly valued way to meet fellowattendees in a 60 minute session. Bring lots of business cards!11.00 Morning RefreshmentsBuilding Tumor Models That Are as Predictive asPossible of Clinical Outcome11.30 Placing the Diversity of Different Tumor Models in theContext of Drug Development in the PharmaceuticalIndustry• Reviewing the retrospective literature regarding thepredictivity of xenograft models to identify the gaps• Placing the appropriate model in the discovery contextusing cell line models with known genetics as anexample• Case study: using patient-derived xenograft models forindication verification in phase 2 decisions Anderson Clark, Director of In Vivo Pharmacology,EMD Serono12.00 Overcoming the Limitations of GEM models to BetterInvestigate Tumor Development – A Pharma Perspective• Assessing the current GEM models used in drugdevelopment and identifying those that induce tumorsresembling human cancer• Understanding how best to model the tumormicroenvironment and co-morbidities using GEM models• Dealing with the expense and limited numbers of mice tonecessitate dose-finding and scheduling experiments Brant Firestone, Senior Investigator, Novartis12.30 Lunch1.30 Using Patient-Derived Explants in Cancer Biologic DrugDiscovery to Better Mimic Tumor Activity in Humans• Understanding how patient-derived explant models (PTX)show a genetic and pathological heterogeneity that leadsto greater clinical relevance• Reviewing internal studies using PTX that havecontributed to the development of personalized oncologytreatments• Using PTX to recapitulate the molecular diversity ofpatient tumors Ching Ching Leow, Senior Scientist, MedImmune2.00 Preclinical Learning and Relevance to ClinicalDevelopment for More Confidence in Candidate Selection• Demonstrating proof of concept to ultimately achieve abreakthrough therapy• Looking at a sharper focus on which preclinical studieshave addressed questions that are critical to development• Selecting an appropriate molecular entity as early aspossible to minimize later stage attrition Li Yu, Research Director, Roche2.30 Is There Really a Lack of Predictive Preclinical Models,or Do We Just Not Apply and Interpret them in anAppropriate Manner? Drug developers have a broad panel of preclinical tumormodels, but applying and interpreting the data in anappropriate manner presents a number of challenges. Thispanel will support you with study design and interpretation. Jan Pinkas, ImmunoGen; Jennifer Michaelson,Jounce Therapeutics; Kuan-Chun Huang, Eisai; ThomasSeyfried, Boston College3.00 Afternoon RefreshmentsNovel Tumor Models and Their Use to Build ConfidenceIn Selected Molecules3.30 Building Multi-Scale Models that Integrate In Vivo and InVitro Results, Ensuring Consistency and Confidence• Understanding how integrating in vitro and in vivo resultscan build confidence in the molecules brought into theclinic• Using multi-scale models to predict outcomes forclinical dosing schedules• Identifying the appropriate methods to reconcile thedifferences between in vitro and in vivo data Vihren Kolev, Scientist, Verastem4.00 Using Orthotopic Tumor Models to Strengthen the Abilityof Selecting Appropriate Molecules• Exploring orthotopic models as a way to minimize thelimitations of traditional xenografts• Using heterotopic tumor models to allow a more realisticassessment of drug efficacy in patients• Addressing the common challenges of orthotopicplatforms, including price and skill set required Pasquale Cirone, Postdoctoral Fellow, Pfizer4.30 Alternative Models for Metastasis and their Use inPredicting the most Appropriate Therapies in the Clinic• Addressing the current lack of appropriate animal modelsfor cancer progression• Introducing new mouse models of progressive melanomato enhance confidence of molecules to be broughtforward• Studying mechanisms associated with drug resistance ofrecurrent BRAF, NRAS and non-BRAF/NRAS melanomas Glenn Merlino, Head of Cancer Modeling, NIH5.00 Chair’s Closing Remarks5.15 Poster SessionDay 1 24th July 2013Keynote Session Panel Session Networking Session
  4. 4. Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comTumor Models Boston 23rd – 25th July 20138.00 Registration, Coffee & Networking8.55 Chair’s Opening Remarks Terri Van Dyke, Head of Cancer Pathways & Mechanisms,NIHApplying and Interpreting Tumor Models to Ensuretheir Relevance to Clinical Tumor Subtypes9.00 Improving Current Strategies for Validating Animal Modelsof Cancer• Studying the mechanisms of cancer etiology at a varietyof levels• Using GEMMS to examine cause/effect relationships ininitiation and progression of disease within the naturalmicroenvironment• Identifying studies that have produced highly penetrantpreclinical cancer models useful for translational studies Terri Van Dyke, Head of Cancer Pathways & Mechanisms,NIH9.30 Hammer or Scalpel? How Expectations of Biology ImpactPreclinical-to-Clinical• Determining the underlying biological mechanism ofaction of anticancer agents• Understanding the differences in response rates causedby host biology (mouse vs. human)• Asking the right preclinical questions to ensure effectivetranslation into a clinical setting Arijit Chakravarti, Senior Scientist,Millennium Pharmaceuticals10.00 Complementary Orthotopic and GEM Models to BetterPredict and Understand Efficacy in the Clinic• Using preclinical tumor models to better predict efficacyin humans• Dealing with cancer heterogeneity using orthotopicmodels to better answer preclinical questions• Addressing common questions related to dosing anddose optimization for clinical trials Birgit Schultes, Senior Director of Translational Research,Momenta Pharmaceuticals10.30 Mastermind Session This session will provide a highly effective and energizingformat for you to access the knowledge of fellow attendeeswhilst collaboratively discussing topics and questionsraised from the meeting.11.15 Morning Refreshments11.45 Overcoming PK/PD Barriers to Link Drug Levels with theBiological Effects in a Tumor• Using tumor models to monitor interactions of a drugand target in the clinic• Establishing in vivo systems that are quantifiable andmeasured over a particular time course• Performing PK/PD experiments to link drug levels to thebiological effects in a tumor Frank Gibbons, Senior Scientist, AstraZeneca12.15 Case Study: Development of a Clinically Relevant Modelof Metastatic Colorectal Cancer• Looking at existing colorectal cancer models and theirdisadvantages• Generating a novel colorectal cancer model thatovercomes many of the current limitations• Using the model for investigating routes of metastaticspread to target organs Kevin Leong, Scientist, Genentech12.45 Lunch1.45 Identifying and Validating Biomarkers by Modeling HumanTumor Growth between Animals and Humans• Overcoming common challenges associated withtranslating data into the clinic• Using methods that address the issues associated withtraditional biomarker selection• Finding the best approaches from selection to efficientbiomarker translation George Naumov, Senior Research Biologist, Merck2.15 Panel Discussion: How Can We Deal With The LowAvailability of Funds and Inadequate Amounts ofTherapeutics in Preclinical Oncology Development The costs incurred by cancer drugs failing in the clinic areskyrocketing. This panel will address how the problem canbe tackled by the recent improvements in tumor models. Jianguo Ma, EMD Serono; Richard Gregory, Sanofi; SharonMcGonigle, Eisai2.45 Afternoon Refreshments3.15 Case Study: Systems Pharmacology Approaches toPreclinically Identify and Test Predictive Biomarkers forClinical Application• Describing challenges inherent in translating drugdistribution properties from mouse to humans• Discussing the use of sensitivity analyses to identifybiomarkers that modulate response• Case study of translating tumor microenvironment-basedbiomarkers into assays intended for clinical application Jonathan Fitzgerald, Proof of Concept Director, MerrimackPharmaceuticals3.45 Using a Platform PBPK Model to Characterize Plasma andTissue Disposition of Monoclonal Antibodies in PreclinicalSpecies and Humans• Developing a PBPK model capable of characterizingplasma and tissue PK of nonspecific monoclonalantibodies• Evaluating the scale up potential of the model bycharecterizing mouse, rat, monkey and human plasmaPK simultaneously• Benefits of using PBPK for preclinical studies to makeinformed decisions Dhaval Shah, Senior Scientist, Pfizer4.15 Chair’s Closing RemarksDay 2 25th July 2013Keynote Session Panel Session Networking Session
  5. 5. Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comTumor Models Boston 23rd – 25th July 2013Preclinical questions surrounding PK/PD, efficacy and toxicity are critical determinantsof drug activity. In addition to the search for better tumor models, there remainsan effort to improve methods for optimizing efficacy predictions and determiningPD drivers of toxicity. A higher level of understanding of such parameters is vital todeveloping improved cancer therapeutics in the clinic.During this workshop, you will understand how to overcome the barriers for accuratePD predictions of toxicity. You will identify the models that produce highly predictivedata sets, especially in preparation for a First-In-Human trial (FIH).Attend this workshop to:• Understand the best methods for effective modelling and use of PD drivers tomitigate differences in host biology• Learn about effective translational modelling of xenograft tumor efficacy for morepredictive data• Choose the right preclinical questions to effectively translate data intorecommendations for the clinicAttendees will leave this workshop knowing how to better address the preclinicalquestions associated with PD predictions of toxicity and dosing schedule.Using non-invasive imaging techniques on your tumor models allows you to greatlyimprove the predictive value of preclinical cancer models. Yet key challengessurrounding the technology and its use need to be overcome for the true potential oftumor imaging to be realized.This workshop will allow you to make huge strides in unravelling the complex biologyof tumors through accurate biomarker identification and appropriate technology.Attend this workshop to:• Learn how to more accurately visualize the impact of your drug on tumor activity tominimize costly attrition in your oncology pipeline• Identify and validate true imaging biomarkers that are highly indicative of disease state• Understand how to adopt the most up to date imaging systems and develop moresophisticated targeted imaging protocolsAttendees will leave with the practical capabilities to enhance their current preclinicalimaging capabilities ensuring that the most accurate predictions are made movingthrough the clinic.Progress in oncology drug development has been slowed by a lack of predictivepreclinical models that reliably predict clinical activity of novel compounds in cancerpatients. Recent increases in the usage of patient-derived tumor xenografts have greatlyenhanced efficacy predictions, drug safety and biomarker validation moving into theclinic. This workshop will address some of the novel approaches using patient derivedxenograft models, together with how they can be used to overcome common issueswith traditional systems.Attend to:• Receive an update on the most innovate patient-derived models available, togetherwith how to integrate them into your preclinical protocols• Learn about cutting edge case studies of where patient-derived tumor xenograftsused to predict drug efficacy• Hear an in-depth description about how these models can be used for biomarkerdevelopment and future applicationsAttendees will leave knowing how to make the most of the newest and most excitingtumor models that will lead to better translational decision making.Jay has led over 20 modeling and simulationprojects and has received a number of awardsfor organizing a team to model antibody-drug-conjugates. Previously, Jay has usedmechanistic models to answer questions aboutproject feasibility, target selection, compoundoptimization and population stratification. Jay’swork also includes implementing mechanismbased PK/PD models and has developed tumorpenetration models for oncology. His work hasspearheaded efforts to model new technologies,combining modeling output with market analysisfor target selection.Dai is an internationally recognized expertin imaging, angiogenesis, and vascular andtumour biology. Dai is an associate professorand the deputy director of the Edwin L SteeleLaboratory, Department of Radiation Oncology,Massachusetts General Hospital and HarvardMedical School. The overall goal of the SteeleLaboratory is to develop a fundamentaland quantitative understanding of theintegrative pathophysiology of tumour growth,angiogenesis, and metastasis, with the ultimategoal of improving prevention, detection, andtreatment of tumours.Workshop leaderJay MettetalSenior ScientistMillennium PharmaceuticalsWorkshop leaderDai FukumuraAssociate ProfessorMassachusetts General HospitalAfter receiving his Ph.D. in Molecular andCellular Biochemistry from Loyola University ofChicago, John was recruited to the Universityof Colorado Denver in 1995 as a post-doctoral fellow in the laboratory of Dr. ArthurGutierrez-Hartmann, M.D., in the Division ofEndocrinology, Metabolism and Diabetes. Hewas promoted to Instructor in 1998 and then toAssistant Professor in 2003 in the Departmentof Medicine. In September 2007, he joined thefaculty of the Division of Medical Oncology.Workshop leaderJohn TentlerAssociate ProfessorUniversity of ColoradoWorkshop A: Modeling and Simulation for EffectiveTranslation of PK/PD, Efficacy and ToxicityWorkshop B: Optimizing Your Current Tumor Imaging Capabilities to moreAccurately Visualize the Impact of a Drug on a Tumor in Your Preclinical ModelWorkshop C: Exploring Patient-derived Tumor Xenograftsto Enhance Data Sets and Improve Efficacy PredictionsDate: 23rd July 2013Time: 8.30am – 11.30amDate: 23rd July 2013Time: 12.00pm – 3.00pmDate: 23rd July 2013Time: 3.30pm – 6.30pm
  6. 6. Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comTumor Models Boston 23rd – 25th July 2013Arijit ChakravartiSenior ScientistMillenniumPharmaceuticalsRichard GregoryLaboratory HeadSanofiJianguo MaAssociate DirectorEMD SeronoJan PinkasDirectorImmunoGenThomas SeyfriedProfessor of BiologyBoston CollegeFrank GibbonsSenior ScientistAstraZenecaVihren KolevScientistVerastemJennifer MichaelsonDirector of ResearchJounce TherapeuticsDhaval ShahSenior ScientistPfizerTerri Van DykeHead of Cancer Pathways& MechanismsNIHLi YuResearch DirectorRocheSharon McGoniglePrinciple ScientistEisaiKuan-chun HuangScientistEisaiJonathan FitzgeraldProof of Concept DirectorMerrimackPharmaceuticalsKevin LeongScientistGenentechGeorge NaumovSenior ResearchBiologistMerckAnderson ClarkDirector of in vivoPharmacologyEMD SeronoNapoleone FerraraDistinguishedProfessorUC San DiegoPasquale CironePostdoctoral FellowPfizerBrant FirestoneSenior ResearchInvestigatorNovartisChing Ching LeowSenior ScientistMedImmuneGlenn MerlinoHead of CancerModelingNIHBirgit SchultesSenior Research DirectorMomentaPharmaceuticalsArijit is a translational pharmacologistworking in the oncology therapeuticarea. His expertise include identifyingmechanisms of action (MoA) of anticanceragents and extending MoA to xenograftsvia efficacy and PK/PD studies.Rick currently leads a Target Identificationand Validation laboratory within theSanofi Oncology Division. His researchefforts focus on the preclinical evaluationof potential therapeutic targets both invitro and in vivo with a special interest inbiologics.Jianguo received his doctorate degree inexperimental therapy and pharmacology inRotterdam Cancer Institute in 2006. Priorto joining EMD Serono, Jianguo previouslyworked in In Vivo Pharmacology at VertexPharmaceuticals. Between 2002-2005 hewas Senior Investigator at Novartis.Jan is currently the Director ofPharmacology at ImmunoGen. Previously,he has worked in roles at Amgen andGenzyme. Jan was a postdoctoral fellowin Dr. Philip Leder’s laboratory in theGenetics Department at Harvard MedicalSchool.Thomas received his Ph.D in Geneticsand Biochemistry in 1976. His researchprogram focuses on gene environmentalinteractions related to complex diseases,such as epilepsy, autism, brain cancer andneurodegenerative diseases.Pasquale has had a career discoveringand characterizing drug targets andsignalling cascades that are critical fordrug discovery. Having worked in drugdevelopment for over a decade, Pasqualehas specialities ranging from smallmolecule drug discovery to biologics.Brant’s work focuses on dealing with thechallenges related to selecting the ‘right’in vivo oncology pharmacology model.His work involves assessing various modelsystems in preclinical drug discovery.Ching joined MedImmune in 2006.She leads an in vivo pharmacologygroup and is the scientific lead onvarious oncology drug developmentteams. Her team conducts preclinicalresearch in several areas of oncologyresearch.Glenn has served as the NIH Ombudsmanfor Animal Welfare, on the Editorial Boardof Cancer Research, on the SteeringCommittee of the Center of Excellence inIntegrative Cancer Biology and Genomics,and is an Executive Editor of Pigment Celland Melanoma Research.Birgit heads a diverse group of in vivo andin vivo biologist and analytical scientists totransition development candidates throughpreclinical research into early clinicaldevelopment. She is responsible fordisease specific animal models and dosingoptimization.Anderson and his team support projectsfrom early discovery through Phase 2clinical trials with in vivo studies involvingefficacy testing, biomarker analyses,combination treatments with standard-of-care agents and PK/PD modeling.Frank is a member of several preclinicaland clinical oncology project teams atAstraZeneca, where he is responsiblefor modeling preclinical PK and PK/PD/efficacy relationships, as well as predictionof human PK and dose.Vihren currently works as a scientist atVerastem. His specialties include assaydevelopment, target validation and HTS.His previous positions were held atMassachusetts General Hospital.Jennifer’s research programs have focusedon monoclonal antibody targeting of TNFfamily member ligands and receptors forthe treatment of cancer or autoimmunedisease. Jennifer joined JounceTherapeutics as Director of Research.Dhaval is a Senior Scientist in the PK/PDmodeling and simulation group at Pfizerinc. He has developed PBPK models forboth small and large molecules.Napoleone is credited with identifyingthe human VEGF gene and describingits proangiogenic properties, whichformed the basis for the development ofGenentech’s bevacizumab. In 2013 he wasawarded the $3 million Breakthrough Prizein Life Sciences for his work.Kevin is a cancer biologist with expertise instem cell biology and metastasis. Followingthe completion of his postdoctoral trainingin the Department of Molecular Biology atGenentech, he transitioned to a Scientistrole within Genentech. His laboratorycurrently focuses on colorectal cancer.George is currently a Senior ResearchBiologist in Oncology at Merck. He waspreviously an Instructor in Surgery atHarvard Medical School and Children’sHospital Boston. George has a seniorlevel, extensive professional experience inpreclinical and translational oncology.Terry, a leader in the use and study ofgenetically modified mice to model humandisease, serves as Chief of the MouseCancer Genetics Program and Directorof the Center for Advanced PreclinicalResearch at the NCI.Li has worked as a Research Directorand DMPK expert at Hoffmann-LaRoche. She has contributed to manyoncology programs from discovery tofinal registration including VELCADE,ZELBORAF and Obinutuzumab.Sharon is a member of the OncologyProduct Creation Unit (PCU) in theDiscovery Biology Department. Sharon’srole is to lead preclinical biology effortson two programs, one of which is in earlydiscovery and one that is currently in earlyclinical development.Kuan-chun is responsible for conductinga series of processes ranging from thediscovery of innovative drug candidatesthrough NDA filing and obtainingapproval.Jonathan leads the pre-POC team forMM-398, liposomal irinotecan, chargedwith the identification and clinicalimplementation of mechanism-baseddiagnostic and combination strategies forimproving the outcome of cancer patients.“Fantastic program andgood atmosphere”Novo NordiskSpeakers
  7. 7. Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comTumor Models Boston 23rd – 25th July 2013When you work with Hanson Wade you work with a partnerfocused on your success. Your investment in both time andmoney needs to generate a return.Our clients want that too and that’s why they work with us. Theywant to reach a targeted audience and eliminate wastage fromtheir marketing activities. They work with us because we deliverresults. We’re proud of this fact.Our research identifies ground breaking issues and allows youto influence industry thinking at an early stage. Our expertiseis recognized and respected by the industry. And our eventsare focused, leading edge and attended by people looking forknowledge before making decisions.Expected Industry Breakdown of AttendeesLarge PharmaBiotechsAcademic ResearchPlatform Technologyand SolutionProvidersUSACanadaEuropeRoWExpected Geographical Breakdown of AttendeesIf your organization needsto raise profile, promoteproducts and services ordevelop new partnershipopportunities in the TumorModels sector, contact:tel: +44 (0)20 3141 8797email: mharley@hansonwade.comMiles Harley“Outstanding meeting with first class speakers.I learned a lot and I will certainly recommendthe meeting to my colleagues”Sanofi Aventis“Very valuable and useful information. One ofthe best meetings I’ve ever attended.”Millennium“It exceeded my expectations. The talkswere high quality and the interaction amongparticipants was excellent.”Genentech“Excellent conference with good presentationsand wonderful networking opportunities”ImmunoGen35%80%5%10%5%25%20%20%Sponsorship Opportunities Working with Hanson WadeAttendee Breakdown Past Sponsor feedback
  8. 8. Tumor Models Boston 23rd – 25th July 2013 Priority Code: WEBTel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.comwww.tumor-models.comRegisterTeam DiscountsVenue and Accommodation* Discounted Not for Profit prices are available. Please visit www.tumor-models.com All discountoffers (including team discounts) require payment at the time of registration to receive any discount.‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date toreceive any discount. All discount offers cannot be combined with any other offer. The conferencefee includes lunch, refreshments and course documentation. The fee does not include travel or hotelaccommodation.Title: Forename: Surname:Job Title: Company/Organization:Email: Direct Manager:Address: Postcode:Country: Direct Telephone:Direct Fax: Mobile:Switchboard: Signature: Date:Number of delegates: Amount: $ Conference Documentation: Credit Card: Visa Mastercard AmexCard No: Valid from: / Expiry Date: /Cardholders name:Signature: Date:Card billing address:Mail:Hanson Wade304 Park Avenue South11th FloorNew York, NY 10010PackageRegister and paybefore Friday3rd May 2013*Register and paybefore Friday7th June 2013*Standard Price*2 day conference+ 3 workshops$3698(save $500)$3798(save $400)$3898(save $300)2 day conference+ 2 workshops$3197(save $400)$3297(save $300)$3397(save $200)2 day conference+ 1 workshop$2698(save $300)$2798(save $200)$2898(save $100)2 day conference $2199(save $200)$2299(save $100) $2399Workshops (each) $599Please select your choice of workshop: Workshop A Workshop B Workshop CFull payment is due on registration. Cancellation and Substitution Policy:Cancellations must be received in writing. If the cancellation is receivedmore than 14 days before the conference attendees will receive a full creditto a future conference. Cancellations received 14 days or less (including thefourteenth day) prior to the conference will be liable for the full fee.A substitution from the same organization can be made at any time.Changes to Conference & Agenda: Hanson Wade reserves the right topostpone or cancel an event, to change the location or alter the advertisedspeakers. Hanson Wade is not responsible for any loss or damage or costsincurred as a result of substitution, alteration, postponement or cancellationof an event for any reason and including causes beyond its controlincluding without limitation, acts of God, natural disasters, sabotage,accident, trade or industrial disputes, terrorism or hostilities.Data Protection: The personal information shown and/or provided by youwill be held in a database. It may be used to keep you up to date withdevelopments in your industry. Sometimes your details may be obtained ormade available to third parties for marketing purposes. If you do not wishyour details to be used for this purpose, please write to: Database Manager,Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJHanson Wade Limited. Registered in England & Wales. Company No: 6752216TERMS & CONDITIONSCode:3463Visit www.tumor-models.comTel: +1 212 537 5898Fax: +1 212 537 5898Email: register@hansonwade.com• 10% discount – 3 delegates• 15% discount – 4 delegates• 20% discount – 5 or more delegatesPlease note that discounts are only valid when three or moredelegates from one company book and pay at the same time.VenueRevere Hotel Boston Common200 Stuart Street, Boston, MA 02116Tel: +1 617 482 1800AccommodationOvernight accommodation is not included in the registrationfee, however accommodation options will be sent out withyour confirmation email upon registering.Delegate DetailsPayment DetailsEvent Prices